发明名称 INHIBITORS OF LRRK2 KINASE ACTIVITY
摘要 The present invention provides compounds having a structure according to Formula I. The invention further provides pharmaceutical compositions including the compounds of the invention and methods of making and using the compounds and compositions of the invention, e.g., in the treatment and prevention of various disorders, such as Parkinson's disease.;
申请公布号 US2016024071(A1) 申请公布日期 2016.01.28
申请号 US201414777254 申请日期 2014.03.12
申请人 ELAN PHARMACEUTICALS, LLC. 发明人 GAROFALO Albert;AUBELE Danielle
分类号 C07D417/12 主分类号 C07D417/12
代理机构 代理人
主权项 1. A compound having a structure according to Formula I:or a salt thereof, wherein: A1 is 5 or 6 membered monocyclic heteroaryl; X is —O—, —S—, —CR6R7—, or —NR8—; Y is —C(O)— or —CH2—; R1 is alkyl, cycloalkyl, heterocycloalkyl, aryl optionally substituted with one or more R9, or heteroaryl optionally substituted with one or more R10, wherein said alkyl is optionally substituted with one or more R11, and wherein said cycloalkyl and said heterocycloalkyl are optionally substituted with one or more R12; R2 and R3 at each occurrence are independently selected from the group consisting of hydrogen, halogen, alkyl, —CN, —NO2, —OR13, —SR13, —NR14R15, —C(O)R16, —S(O)mR16, cycloalkyl, and heterocycloalkyl, wherein said alkyl is optionally substituted with one or more substituents selected from the group consisting of halogen, —CN, —NO2, ═O, —OR13, —SR13, —NR14R15, ═NR15, —C(O)R16, —S(O)mR16, cycloalkyl, and heterocycloalkyl, or said alkyl is optionally substituted with one or more R11, or R2 and R3 combined form ═O or ═NR, or one set of R2 and R3 attached to the same carbon can combine with the carbon to which they are attached to form a carbocyclic ring or heterocyclic ring, wherein each ring is optionally substituted with one or more substituents selected from the group consisting of hydrogen, halogen, alkyl, —CN, —NO2, ═O, —OR13, —SR13, —NR14R15, ═NR15, —C(O)R16, —S(O)mR16, cycloalkyl, and heterocycloalkyl, wherein cycloalkyl, and heterocycloalkyl are optionally substituted with one or more R12 and wherein said alkyl is optionally substituted with one or more substituents selected from the group consisting of halogen, —CN, —NO2, ═O, —OR13, —SR13, —NR14R15, ═NR15, —C(O)R16, —S(O)mR16, cycloalkyl, and heterocycloalkyl; R4 is hydrogen or alkyl; R5 at each occurrence is independently selected from the group consisting of halogen, alkyl, —CN, —NO2, —OR17, —SR17, —NR18R19, —C(O)R20, —S(O)mR20, —C(O)OR17, —OC(O)R20, —C(O)NR18R19, —NR18C(O)R20, —S(O)2NR18R19, —NR18S(O)2R20, cycloalkyl, and heterocycloalkyl, wherein said alkyl is optionally substituted with one or more substituents selected from the group consisting of halogen, —CN, —NO2, ═O, —OR17, —SR17, —NR18R19, ═NR19, —C(O)R20, —S(O)mR20, —C(O)OR17, —OC(O)R20, —C(O)NR18R19, —NR18C(O)R20, —S(O)2NR18R19, —NR18S(O)2R20, cycloalkyl, and heterocycloalkyl, and wherein said cycloalkyl and heterocycloalkyl are optionally substituted with one or more R11; R6 and R7 are independently selected from the group consisting of hydrogen, halogen, alkyl, —CN, —NO2, —OR13, —SR13, —NR14R15, —C(O)R16, —S(O)mR16, cycloalkyl, and heterocycloalkyl, Wherein said alkyl is optionally substituted with one or more substituents selected from the group consisting of halogen, —CN, —NO2, ═O, —OR13, —SR13, —NR14R15, ═NR15, —C(O)R16, —S(O)mR16, cycloalkyl and heterocycloalkyl, and wherein said cycloalkyl and heterocycloalkyl are optionally substituted with one or more R11; R8 is selected from the group consisting of hydrogen and alkyl, wherein said alkyl is optionally substituted with one or more substituents selected from the group consisting of halogen, —CN, —NO2, ═O, —OR13, —SR13, —NR14R15, ═NR15, —C(O)R16, —S(O)mR16, and N-linked heterocycloalkyl; R9 and R10 at each occurrence are independently selected from the group consisting of halogen, alkyl, —CN, —NO2, —OR17, —SR17, —NR18R19, C(O)R20, —S(O)mR20, —C(O)OR17, —OC(O)R20, —C(O)NR18R19, —NR18C(O)R20, —S(O)2NR18R19, —NR18S(O)2R20, cycloalkyl and heterocycloalkyl, wherein said alkyl is optionally substituted with one or more halogen, cycloalkyl, —CN, —NO2, ═O, —OR17, —SR17, —NR18R19, ═NR19, —C(O)R20, —S(O)mR20, —C(O)OR17, —OC(O)R20, —C(O)NR18R19, —NR18C(O)R20, —S(O)2NR18R19, —NR18S(O)2R20, cycloalkyl and heterocycloalkyl, and wherein said cycloalkyl and heterocycloalkyl are optionally substituted with one or more R12; R11 at each occurrence is independently selected from the group consisting of halogen, —CN, —NO2, ═O, —OR17, —SR17, —NR18R19, ═NR19, C(O)R20, —S(O)mR20, —C(O)OR17, —OC(O)R20, —C(O)NR18R19, —NR18C(O)R20, —S(O)2NR18R19, —NR18S(O)2R20, cycloalkyl optionally substituted with one or more R12, heterocycloalkyl optionally substituted with one or more R12, aryl optionally substituted with one or more R9, or heteroaryl optionally substituted with one or more R10; R12 at each occurrence is independently selected from the group consisting of halogen, alkyl, haloalkyl, —OH, ═O, alkoxy, haloalkoxy, —SH, ═S, —S(O)q-alkyl, —S(O)q-haloalkyl, —NH2, alkylamino, dialkylamino, and N-linked-heterocycloalkyl; R13, R14, R15, R17, R18, and R19, at each occurrence are independently selected from the group consisting of hydrogen and alkyl wherein said alkyl is optionally substituted with one or more substituents selected from the group consisting of halogen, —OH, ═O, alkoxy, haloalkoxy, —SH, ═S, —S(O)q-alkyl, —S(O)q-haloalkyl, —NH2, alkylamino, dialkylamino, and N-linked-heterocycloalkyl; R16 and R20 at each occurrence are independently alkyl optionally substituted with one or more substituents selected from the group consisting of halogen, —OH, ═O, alkoxy, haloalkoxy, —SH, ═S, —S(O)q-alkyl, —S(O)q-haloalkyl, —NH2, alkylamino, dialkylamino, and N-linked-heterocycloalkyl; m is 1 or 2; n is 1 or 2; p is 0, 1, 2, or 3; and q is 0, 1, or 2;provided, however, that the compound is other than
地址 Allegan MI US